quinta-feira, 30 de outubro de 2014

New Cancer Drug Benefits Half Of Patients In Trial, With Limitations - Forbes

New Cancer Drug Benefits Half Of Patients In Trial, With Limitations - Forbes | new - Google News | October 30, 2014 at 10:43AM









New Cancer Drug Benefits Half Of Patients In Trial, With Limitations

Forbes

A new cancer drug benefited 51% of stage III and IV melanoma patients during a phase II trial, achieving complete response (total cancer disappearance) in 26% during the treatment period. That was all in just 16 weeks of treatment, suggesting this drug ...







October 30, 2014 at 10:43AM | new - Google News

New Cancer Drug Benefits Half Of Patients In Trial, With Limitations - Forbes

new - Google News

Nenhum comentário:

Postar um comentário